Backtesting is not the way forward for structured products

The use of backtesting to provide investors with a useful way of making investment decisions when buying structured products continues to be discredited, so isn't it time for future projections only?

Richard Jory
Richard Jory, Structured Products editor

There is peril if you look back, confusion if you look forward, but no way that you can stand still. The backtesting of structured products is considered poor form by many regulators, some of which are driven to ban the whole practice, while others express doubt about the practicality of using future projections to provide any reliable or understandable assessment of a structured product's quality.

The extent of views on backtesting range from those of the International Organization of

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Register

Want to know what’s included in our free membership? Click here

This address will be used to create your account

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here